Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011043 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
A Phase 1 study of Systemic Lupus Erythematosus, sponsored by Climb Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 18
- Study locations
NCT07011043: Recruiting Phase 1 study of Systemic Lupus Erythematosus, sponsored by Climb Bio.
NCT07011043 is a Phase 1 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by Climb Bio. The registered enrollment target is 30 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07011043, a Phase 1 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by Climb Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 18
- Study locations
Study Summary
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Primary Outcome
Number of participants experiencing TEAEs, graded per NCI CTCAE v5.0.
Conditions Studied
Interventions
- DRUG Budoprutug
Study Locations (18)
Other
- Climb Bio Investigative Site# 359101 - Plovdiv
- Climb Bio Investigative Site# 359102 - Sofia
- Climb Bio Investigative Site #995102 - Tbilisi
- Climb Bio Investigative Site #995101 - Tbilisi
- Climb Bio Investigative Site #100103 - Caguas
- Climb Bio Investigative Site# 400101 - Cluj-Napoca
- Climb Bio Investigative Site# 340102 - A Coruña
- Climb Bio Investigative Site #380102 - Ivano-Frankivsk
- Climb Bio Investigative Site #380103 - Kyiv
- Climb Bio Investigative Site #380106 - Kyiv
- Climb Bio Investigative Site #380101 - Ternopil
- Climb Bio Investigative Site #380104 - Vinnytsia
- Climb Bio Investigative Site #380105 - Vinnytsia
Texas
- Climb Bio Investigative Site #100104 - Allen
- Climb Bio Investigative Site #100101 - San Antonio
Thessaloniki
- Climb Bio Investigative Site# 300102 - Exochi
- Climb Bio Investigative Site# 300103 - Thessaloniki
Barcelona
- Climb Bio Investigative Site# 340101 - Sabadell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT07011043 shows while recruiting
NCT07011043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Budoprutug is the first listed.
NCT07011043 lists 18 locations in 4 states (Other, Texas, Thessaloniki).
Frequently Asked Questions
What is clinical trial NCT07011043 about?
NCT07011043 is a clinical study titled "A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)". The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
What is the current status of trial NCT07011043?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-07-10. Estimated completion is 2027-04.
What conditions does trial NCT07011043 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT07011043?
The interventions under investigation include: Budoprutug (DRUG).
Who is sponsoring clinical trial NCT07011043?
This trial is sponsored by Climb Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011043 being conducted?
This trial has 18 study locations across Texas, Thessaloniki, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07011043's enrollment target sits among peer trials
30 83rd of 99 higher than 16 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI